RU-2861544-C1 - METHOD FOR REGENERATION OF DAMAGED PERIPHERAL NERVES

Abstract

FIELD: medicine; neurology. SUBSTANCE: invention can be used for regeneration of damaged peripheral nerves. Administration of a medicinal preparation based on insulin-like growth factor-1 (IGF-1) is carried out, wherein intramuscular injection of a solution of IGF-1 in 0.9% sodium chloride solution with an active substance concentration of 300 ng/ml is performed. EFFECT: acceleration of regeneration and restoration of the functional activity of nerve fibres due to activation of the IGF-1 MAPK/ERK signalling pathway, which stimulates the expression of remyelination genes, stabilises the protein composition of nerves, and intensifies DNA synthesis in damaged tissues at early stages after injury. 1 cl, 2 dwg, 1 ex

Inventors

• Revin Viktor Vasilevich
• Parchaikina Marina Vladimirovna
• Revina Elvira Sergeevna
• Kuzmenko Tatiana Pavlovna
• Zavarykina Anastasiia Viacheslavovna
• Gruniushkin Igor Pavlovich

Dates

Publication Date

20260505

Application Date

20250924

Claims (1)

1. A method for the regeneration of damaged peripheral nerves, including the administration of a medicinal product based on insulin-like growth factor-1 (IGF-1), characterized in that the product is administered intramuscularly at a dose of 100 ng/kg for 21 days, using a solution of IGF-1 in a 0.9% sodium chloride solution with an active substance concentration of 300 ng/ml.

Description

The invention relates to the field of regenerative medicine and can be used to accelerate the process of restoration of damaged somatic nerves. The problem of somatic nerve regeneration remains one of the most pressing and poorly understood in biology and medicine due to the lack of effective treatments. Current approaches to treating damaged somatic nerves are unable to sustain long-term nerve cell survival and neurite growth—key factors in nerve regeneration. Given the significance of this problem, in recent years, research has shown increasing interest in identifying potential therapeutic agents—substances that enhance neuroprotection and stimulate regenerative processes. A pharmaceutical composition for local and external use for the treatment of traumatic and postoperative injuries of the peripheral nervous system is known, characterized in that it contains a clobetasol solution at a concentration of 0.5 mg/kg (RU 2745868C1, IPC A61K 31/573, A61P 25/02, published 02.04.2021). Clobetasol is known to enhance myelination of oligodendrocyte precursor cells. Furthermore, clobetasol, at significantly lower concentrations, is more potent than other topical corticosteroids. Clobetasol (0.5 mg/kg) stimulates the synthesis of cytoskeletal proteins in nerve cells. A positive effect on the synthesis of specific proteins associated with axonal growth is also observed. A disadvantage is that long-term use of high-dose topical glucocorticosteroids (GCS) can be accompanied by systemic absorption, leading to the development of hypercorticism symptoms. Long-term use of topical GCS should be avoided, as it can lead to adrenal suppression. A pharmaceutical composition is known for local and external use for the treatment of traumatic and postoperative injuries of the peripheral nervous system, characterized in that it contains stefaglabrin sulfate and a hydrophilic base in the form of a hydrophilic substance or a physiologically acceptable mixture of hydrophilic substances in combination with components that provide the specified requirements for the base depending on the dosage form of the drug, with the following ratio of components (wt.%): stefaglabrin - 0.001-2.0; hydrophilic base - the rest (RU 2369388, IPC A61K 31/00, A61K 36/59, A61K 9/08, published 10.10.2009). This medication, stefaglabrin sulfate 0.25% solution, is a medication that acts primarily on the peripheral nervous system. It has anticholinesterase activity; it inhibits (suppresses the enzyme activity of) true and false cholinesterase. Stefaglabrin is an alkaloid isolated from the tubers and roots of Stephanie glabra. Contraindications for this medication include epilepsy, hyperkinesia (involuntary muscle contractions of the limbs), bronchial asthma, angina pectoris, and bradycardia (slow pulse). The disadvantage is that it does not stimulate reparative processes. A known invention possessing antioxidant and anti-inflammatory properties is characterized by the fact that it contains the polyphenol curcumin and a combination of acids: malic, citric, and acetic, and is used to treat inflammatory diseases. The polyphenol acts on targets of multiple pathways, including MAPK (mitogen-activated protein kinase), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and STAT3 (signal transducer and activator of transcription 3). Thus, it may participate in accelerating regenerative processes. The invention contains from 2 mg to 200 mg of the substance and is administered in the form of a food supplement (RU 2532384C2, IPC A61K 31/12, A61K 9/107, A61K 9/48, published 10.11.2011). Curcumin helps reduce oxidative stress by acting on and increasing the levels of anti-inflammatory markers TNF-α (Tumor Necrosis Factor alpha), IL-1β, and IL-6 (interleukin-1β and interleukin-6). A significant drawback of curcumin is its poor intestinal absorption and rapid systemic elimination from the body. This contributes to a reduced overall clinical effect. An invention related to biotechnology, specifically an aptamer that specifically binds to nerve growth factor (NGF), has potential medical applications as an anti-inflammatory or analgesic agent. The invention enables the production of an aptamer capable of forming a secondary structure. The invention makes it possible to obtain an aptamer capable of inhibiting NGF activity with an IC 50 of 1 nM or less (RU 2633510C2, IPC C12N 15/115, C12N 15/09, A61K 31/712, A61P 29/00, A61P 37/04, published 12.10.2017). NGF is well known to play a key role in the nervous system. It has been shown to support the survival of cholinergic neurons. Furthermore, since intracerebral administration of NGF reduces memory impairment in aged rats, it is expected to be a therapeutic agent for senile dementia. NGF is also associated with inflammation, with increased NGF expression observed in patients with inflammatory diseases and in animal models of inflammation. Examples of such diseases include systemic lupus erythematosus, multiple sc